Published On : August 2026
Distribution models across the Italian pharmaceutical wholesale distribution market span full-line wholesalers, short-line distributors, specialty distributors, pre-wholesale operators and direct-to-pharmacy and direct-to-hospital arrangements.
Channels run alongside them, covering wholesale distribution, retail pharmacy networks, franchise and cooperative networks, e-pharmacy fulfilment support and institutional healthcare supply.
The two are connected, because a distribution model is largely defined by which customers it can economically reach.
What separates the models is range and frequency rather than the products themselves, since most of them carry overlapping catalogues.
A full-line operator commits to breadth and to delivery reliability; a short-line operator commits to a narrower range at better terms.
That trade-off is the fundamental structure of pharmaceutical wholesaling everywhere, and Italy's version of it is shaped by how many small customers there are to serve.
Serving twenty thousand pharmacies with daily or twice-daily delivery is a formidable logistics undertaking, and it is what full-line distribution exists to do.
The cost of that undertaking is why full-line margins are thin and why distributors have looked to services rather than to distribution for margin improvement.
Direct models bypass wholesaling entirely, with manufacturers supplying pharmacies or hospitals themselves, and they have grown where product value justifies the cost.
Pre-wholesale sits at the other end, handling product on a manufacturer's behalf before it reaches wholesalers at all.
This page describes the structures and how they relate, and provides no medical, clinical or pharmaceutical advice of any kind.
Most distributors operate more than one model simultaneously, since a single infrastructure can support full-line, specialty and pre-wholesale activity at marginal additional cost.
A full-line pharmaceutical wholesaler carries the complete range of products a pharmacy might be asked to dispense, which runs to tens of thousands of lines.
The breadth involved spans essentially all of the product categories each model carries, from prescription medicines through to consumer healthcare and devices.
Delivery frequency is the model's other defining commitment, with multiple deliveries per day common in urban areas and at least daily service expected generally.
That frequency exists because a pharmacy cannot hold deep stock and must be able to obtain an unusual item quickly when a patient presents a prescription for it.
The commercial consequence is that full-line distribution is judged on service availability rather than on price, since a missed line has a cost the customer feels immediately.
Warehouse automation and route optimisation are where full-line operators compete on cost, because the underlying service commitment is not negotiable.
Short-line distributors carry a narrower range, typically concentrating on higher-volume lines where they can offer better terms than a full-line operator can sustain.
The model works because a pharmacy can buy its predictable volume from a short-line supplier and use a full-line wholesaler for everything else.
That dual sourcing is common practice and it is a structural pressure on full-line economics, since the profitable predictable volume leaves while the obligation to carry everything remains.
Distributors respond by differentiating on service, digital integration and commercial support rather than attempting to match short-line pricing.
The balance between the two models is one of the more consequential commercial dynamics in this market.
Service level is measured explicitly in this business, typically as the proportion of ordered lines supplied complete and on time, and customers track it closely.
Pre-wholesale operators handle product on behalf of manufacturers before it enters the wholesale channel, providing storage, order processing and onward distribution to wholesalers.
The model exists because a manufacturer entering a market needs local warehousing and regulatory-compliant handling without building it themselves.
It is particularly useful to smaller manufacturers, to companies without an Italian operation, and to products whose volumes do not justify dedicated infrastructure.
The pre-wholesaler is a service provider to the manufacturer rather than a trading business, which makes its economics quite different from wholesaling.
Revenue comes from fees for services performed rather than from margin on product bought and resold, which removes inventory risk entirely.
That fee-based structure is attractive precisely because it is insulated from the margin compression affecting trading wholesalers.
Pre-wholesale requires the same regulatory authorisation and quality systems as wholesaling, since the product is in the operator's custody throughout.
Manufacturers using pre-wholesale retain title to their product and therefore retain visibility of where it goes, which is valuable for commercial and traceability reasons alike.
The model also supports direct-to-pharmacy arrangements, since a pre-wholesaler can execute deliveries a manufacturer has contracted directly.
Growth in pre-wholesale has followed the growth of specialty products, whose manufacturers frequently want closer control of distribution than the traditional channel allows.
For distribution groups, pre-wholesale is a service line that uses existing infrastructure to generate fee revenue rather than trading margin.
Because the operator never owns the product, its balance sheet looks quite different from a wholesaler's, carrying no inventory against the volumes it handles.
Specialty distributors handle products whose storage, handling, traceability or delivery requirements exceed what standard distribution provides.
The category has grown quickly because pharmaceutical output has shifted toward biologics, cell and gene products and other treatments with demanding handling profiles.
Specialty distribution is a capability business rather than a scale business, since what is being sold is the ability to handle product correctly.
That capability requires validated temperature-controlled infrastructure, monitored transport and documentation systems considerably beyond standard practice.
Investment must generally be made ahead of the volumes that will use it, which is a real barrier and a reason capability gaps exist.
The report's own competitive mapping identifies specialty gaps as an opportunity, which reflects volumes growing faster than capability has been built.
Manufacturers of specialty products frequently restrict which distributors may handle them, which makes qualification a prerequisite rather than a commercial preference.
Those restrictions give qualified distributors a protected position, since a manufacturer cannot simply switch to whichever distributor quotes lowest.
Delivery in specialty distribution is frequently to a named site or clinician rather than to a general pharmacy stock, which changes the operational model.
Volumes per line are low and values per unit are high, which inverts the economics of standard wholesaling almost entirely.
For distributors, specialty is where margin is genuinely available, and it is where most strategic investment in this market is currently directed.
Patient support programmes sometimes attach to these products, and distributors participating in them take on coordination work well beyond conventional supply.
Direct models involve manufacturers supplying pharmacies or hospitals themselves rather than selling into the wholesale channel.
Direct-to-pharmacy arrangements give a manufacturer control over how its products reach the market, including pricing, terms and stock allocation.
The motivation is commonly commercial rather than logistical, since a manufacturer selling directly captures the distribution margin and controls the customer relationship.
Execution frequently still runs through a logistics provider or pre-wholesaler, so direct means direct commercially rather than physically.
The model works best for higher-value products where the cost of direct service is justified by the margin at stake.
It works poorly for broad low-value ranges, where the cost of serving many pharmacies individually would exceed any margin captured.
Direct-to-hospital arrangements are more established, since hospitals buy in larger quantities through tenders and can be served economically without an intermediary.
Hospital supply also involves products that never pass through retail pharmacy at all, which removes any reason to route them through retail distribution.
Wholesalers respond to direct models by offering services manufacturers cannot easily replicate, including market access support and commercial infrastructure.
The balance between direct and wholesale supply has moved back and forth over time, and it varies considerably by product category.
For pharmacies, direct arrangements mean managing more supplier relationships, which is precisely the burden wholesaling exists to remove.
Manufacturers weighing a direct model must also weigh what they give up, since wholesalers absorb credit risk and payment collection across thousands of small accounts.
Beyond distribution models sit the pharmacy networks that receive the product, and Italy's network structure is unusually varied.
Which network a pharmacy belongs to shapes how it buys, and the customers each channel reaches differ substantially in purchasing behaviour as a result.
Retail pharmacy networks in the corporate sense are relatively new in Italy, having become possible only after ownership rules changed in 2017.
Franchise networks offer independent pharmacy owners a shared brand, purchasing arrangements and commercial support while leaving ownership with the pharmacist.
The model suits Italy well precisely because it delivers scale benefits without requiring the ownership consolidation that the market's history resists.
Cooperative networks are the most distinctive structure in Italian pharmaceutical distribution and much less common elsewhere in Europe.
A pharmacist cooperative is owned by the pharmacies it supplies, which means its members are simultaneously its customers and its owners.
That structure changes the commercial relationship fundamentally, since the cooperative's purpose is to serve its members rather than to extract margin from them.
Cooperatives compete with commercial wholesalers for the same customers, and their ownership structure is a genuine competitive advantage in member loyalty.
E-pharmacy fulfilment support is the newest channel, with distributors providing logistics behind online pharmacy operations rather than selling directly.
Institutional healthcare supply completes the picture, covering hospitals and healthcare institutions that buy through entirely different processes from retail pharmacy.
Network membership is not exclusive in every case, and pharmacies frequently maintain relationships across more than one supply arrangement simultaneously.
A full-line wholesaler carries the complete range of products a pharmacy might dispense, running to tens of thousands of lines, with daily or more frequent delivery. It is judged on service availability rather than price, since a missed line has an immediate cost to the customer.
A pre-wholesaler handles product on a manufacturer's behalf before it enters the wholesale channel, providing storage, order processing and onward distribution. It earns fees for services performed rather than margin on product, which removes inventory risk.
Direct-to-pharmacy means a manufacturer supplies pharmacies itself rather than selling into the wholesale channel, capturing the distribution margin and controlling the customer relationship. Execution frequently still runs through a logistics provider, so it is direct commercially rather than physically.
A pharmacist cooperative is owned by the pharmacies it supplies, so its members are simultaneously its customers and its owners. The structure is distinctive to Italian pharmaceutical distribution and gives cooperatives a genuine advantage in member loyalty.